Construction of phosphorylatable chimeric monoclonal antibody CC49 with a tyrosine Src kinase recognition site

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 725-732

  Lin, Lei ^a   Gillies, Stephen D ^b   Schlom, Jeffrey ^c   Pestka, Sidney ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Lexigen Pharmaceuticals Corp   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer diagnosis; Cancer therapy; Chimeric antibody; Monoclonal antibody; Protein kinase; Tumor associated antigens; Tyrosine protein kinase; Tyrosine protein kinase recognition site

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN KINASE P60;

ANTIBODY PRODUCTION; ARTICLE; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CHIMERA; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; HUMAN; IMMUNOGENICITY; MOLECULAR RECOGNITION; PREDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0031694508     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.725     Document Type: Article

References (38)

1. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG and Podoloff DA: Phase II radioimmunotherapy trial with 1311-CC49 in colorectal cancer. Cancer 73: 1057-1066, 1994.
2. Perkins AC, Vincent RM, Wastie ML, Denton GW, Amar S and Hardcastle JD: Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72,3 (Oncoscint CR-OV): effect of administered activity. Nucl Med Commun 15: 981-990, 1994.
3. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94: 297-312, 1993.
4. Schlom J: Monoclonal antibodies in cancer therapy. In: Biological Therapy of Cancer. 2nd edition. De Vita VT, Hellman S and Rosenberg SA (eds.) J.B. Lippincott Company, Philadelphia, pp507-521, 1995.
5. Colcher D, Horan Hand P, Nuti M and Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78: 3199-3203, 1981.
6. Nuti M, Teramoto YA, Mariani-Costantini R, Horan Hand P, Colcher D and Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539-545, 1982.
7. Stramignoni D, Bowen R, Atkinson B and Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 31: 543-552, 1983.
8. Thor A, Ohuchi N, Szpak CA, Johnson WW and Schlom J: The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 46: 3118-3124, 1986.
9. Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM and Schlom J: Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 47: 1185-1189, 1987.
10. Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, et al: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MoAb B72.3. Int J Cancer 39: 50-59, 1987.
11. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM and Schlom J: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218-4224, 1987.
12. Carrasquillo J, Sugarbaker P, Colcher D, Reynolds J, Esteban J, Begent G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J and Larson SM: Radioimmunoscintigraphy of colon cancer with iodine 131-labeled B72.3 monoclonal antibody. J Nucl Med 29: 1022-1030, 1988.
13. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P and Schlom J: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 48: 4588-4596, 1988.
14. Molinolo A, Simpson JF, Thor A and Schlom J: Enhanced tumor binding using immunohistochcmical analyses by secondgeneration anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 51: 1291-1298, 1990.
15. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1: 1447-1454, 1995.
16. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J and Colcher D: High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 15: 1518-1528, 1997.
17. 131l-labcled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 4: 643-651, 1998.
18. Meredith RF, Partridge EE, Alvarez RD, Khazaeli MD, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J and Lo Buglio AF: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37: 1491-1496, 1996.
19. Li B-L, Langer JA, Schwartz B and Pestka S: Creation of phosphorylation sites in proteins: construction of a phosphorylatable human interferon a. Proc Natl Acad Sci USA 86: 558-562, 1989.
20. Zhao X-X, Li B-L, Langer JA, van Piper G and Pestka S: Construction and phosphorylation of a fusion protein Hu-IFN-αA/γ. Anal Biochem 178: 342-347, 1989.
21. Mariano TM and Pestka S: Receptor-binding studies. In: Cytokines - A Practical Approach. Balkwill FR (ed.) Oxford University Press, Oxford, pp95-108, 1991.
22. Wang P, Izotova L, Mariano TM, Donnelly RJ and Pestka S: Construction and activity of phosphorylatable human interferon-αB2 and interferon-αA/D. J Interferon Res 14: 41-46, 1994.
23. Lin L, Daugherty B, Schlom J and Pestka S: Construction of phosphorylatable monoclonal antibody to a tumor associated antigen. Cancer Res 56: 4250-4254, 1996.
24. Lin L, Gillies SD, Lan Y, Izotova L, Wu W, Schlom J and Pestka S: Construction of phosphorylatable chimeric monoclonal antibody CC49. Int J Oncol 13: 115-120, 1998.
25. Foxwell BM, Band HA, Long J, Jeffery WA, Snook D, Thorpe PE, Watson G, Parker PJ, Epenetos AA and Creighton AM: Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. Br J Cancer 57: 489-493, 1988.
26. Dagan S, Tzehoval E, Fridkin M and Feldman M: Tuftsin and tuftsin conjugates potentiate immunogenic processes: effects and possible mechanisms. J Biol Response Mod 6: 625-636, 1987.
27. Cheng HC, Nishio H, Hatase O, Ralph S and Wang JH: A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of src-family tyrosine kinases. J Biol Chem 267: 9248-9256, 1992.
28. Gillies SD, Lo K-M and Wesolowski JS: High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125: 191-202, 1989.
29. Gillies SD, Young D, Lo K-M, Foley SF and Reisfeld RA: Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10: 347-356, 1991.
30. Nishimura A, Morita M, Nishimura Y and Sugino Y: A rapid and highly efficient method for preparation of competent Escherichia coli cells. Nucleic Acids Res 18: 6169, 1990.
31. Potter H, Weir L and Leder P: Enhancer-dependent expression of human N immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci USA 81: 7161-7165, 1984.
32. Dc Martino JA, Daugherty BL, Law MF, Cuca GL, Alves K, Silberklang M and Mark GE: Rapid humanization and expression of murine monoclonal antibodies. Antibody Immunoconj Radiopharm 4: 829-835, 1991.
33. c-src-related tyrosine kinase that effectively phosphorylates a synthetic peptide derived from p34cdc2. J Biol Chem 266: 2557-2566, 1991.
34. Pestka S: Studies in transfer ribonucleic acid-ribosome complex. J Biol Chem 247: 4669-4678, 1972.
35. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB and Schlom J: Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235: 895-898, 1987.
36. Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α interferon treatment. Cancer Res 44: 3208-3214, 1984.
37. Guadagni F, Schlom J, Johnson WW, Szpak C, Goldstein D, Smalley R, Simpson JF, Borden EC, Pestka S and Greiner JW: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81: 502-512, 1989.
38. Scatchard G: Attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.